Ensoma is a biotechnology company focused on developing in vivo engineered cellular medicines. The company leverages its proprietary platform to create transformative gene therapies for patients with severe genetic disorders.

Ensoma

Ensoma /en’sōmə/ is derived from the Greek phrase “en soma,” meaning in the body. We develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within. We have a bigger, bolder vision for genomic medicine: treatments as versatile, precise, and far-reaching as the body’s own cells. Our team takes inspired action towards pushing beyond today’s possible with the goal of delivering a one-time, off-the-shelf treatment to patients everywhere.

RIT Capital Partners

5AM Ventures

Alexandria Venture Investments

Cormorant Asset Management

F-Prime Capital

SymBiosis LLC

Takeda Ventures

Viking Global Investors

Bioluminescence Ventures

Delos Capital

Kite Pharma

Qatar Investment Authority

Catalio Capital Management

Solasta Ventures

Fred Hutchinson

Mirae Asset

Metric
Company Name	Ensoma
Symbol
MSH ID	COM:ENSOMA
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	121
Website	ensoma.com
LinkedIn	ensomabio
Founders

Metric
Market Cap	11.79M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score	10.21
28-Day Growth Score	16.24
90-Day Growth Score	13.93
365-Day Growth Score	12.88

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:ENSOMA

Ensoma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue